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AbsTrACT
background: Diabetics, especially insulin -treated diabetics, 
have more extensive coronary atherosclerosis and impaired 
vascular remodeling. Our objective was to evaluate in-hospital 
results of contemporaneous percutaneous coronary intervention 
(PCI) in a consecutive series of diabetics treated with (ITD) or 
without (NITD) insulin. Methods: Retrospective analysis of a 
multicenter registry with 1,896 diabetics, of which 397 (20.9%) 
were from the ITD group and 1,499 from the NITD group. 
Major adverse cardiac and cerebrovascular events (MACCE) 
were compared between groups. results: The ITD group showed 
a higher rate of women and of patients with chronic renal 
failure, but showed less complex angiographic characteristics 
when compared to the NITD group, with fewer B2/C lesions, 
thrombus -containing lesions, occlusions and TIMI 0/1 flow prior 
to PCI. We treated 1.4 ± 0.7 vessels/patient with 1.3 ± 0.7 
stents/patient in each group and the diameter and length of 
stents were not different between groups. Clinical in -hospital 
outcomes showed no differences regarding the occurrence 
of MACCE (3.8% vs. 2.8%; P = 0.40), stroke (0 vs. 0.1%; 
P > 0.99), myocardial infarction (2.5% vs. 2.1%; P = 0.72), 
emergency cardiovascular bypass graft surgery (0 vs. 0.1%; 
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rEsUMO
Intervenção Coronária Percutânea em Diabéticos 
Tratados com Insulina
Introdução: Diabéticos, especialmente os tratados com in-
sulina, apresentam aterosclerose coronária mais extensa e 
remodelamento vascular comprometido. Nosso objetivo foi 
avaliar os resultados hospitalares contemporâneos da inter-
venção coronária percutânea (ICP) em série consecutiva de 
diabéticos tratados com (DMI) ou sem (DMNI) insulina. Mé-
todos: Análise retrospectiva de um registro multicêntrico com 
1.896 diabéticos, dos quais 397 (20,9%) eram do grupo DMI 
e 1.499, do grupo DMNI. Comparamos os eventos cardíacos 
e cerebrovasculares adversos maiores (ECCAM) entre os dois 
grupos. resultados: O grupo DMI mostrou maior proporção 
de mulheres e de portadores de insuficiência renal crônica, 
mas apresentou características de menor complexidade an-
giográfica, quando comparado ao grupo DMNI, com menor 
número de lesões tipo B2/C e presença de trombo, oclusões 
e lesões com fluxo TIMI 0/1 pré-ICP. Foi tratado 1,4 ± 0,7 
vaso/paciente com 1,3 ± 0,7 stent/paciente em cada grupo, 
e o diâmetro e a extensão dos stents não diferiram entre os 
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grupos. Os desfechos clínicos hospitalares não mostraram 
diferença quanto à ocorrência de ECCAM (3,8% vs. 2,8%; 
P = 0,40), acidente vascular cerebral (0 vs. 0,1%; P > 0,99), 
infarto do miocárdio (2,5% vs. 2,1%; P = 0,72), cirurgia 
de revascularização miocárdica de emergência (0 vs. 0,1%; 
P > 0,99) ou óbito (1,5% vs. 0,8%; P = 0,24). Foram predi-
tores independentes de ECCAM, em diabéticos, sexo feminino, 
pacientes com doença multiarterial e fluxo TIMI 0/1 pré-ICP. 
Conclusões: Em nosso estudo, o DMI não foi preditor inde 
pendente de ECCAM hospitalares.
DEsCrITOrEs: Diabetes mellitus. Insulina. Angioplastia. Stents.
P > 0.99) or death (1.5% vs. 0.8%; P = 0.24). Independent 
predictors of MACCE in diabetics were the female gender, 
patients with multivessel disease and TIMI 0/1 flow prior to 
PCI. Conclusions: In our study, ITD was not an independent 






DEsCrIPTOrs: Diabetes  mellitus. Insulin. Angioplasty. Stents.
D ata from the Framingham study demonstrated that the incidence of type 2 diabetes has doubled in the last 30 years.1 It is estimated that the total 
number of diabetics worldwide will increase from 171 
million in 2000 to 366 million in 2030.2 Brazil follows 
the same worldwide trend, and is among the ten coun-
tries with the highest absolute number of individuals 
with diabetes.3,4
Type 2 diabetes is a progressive disease, in which 
peripheral insulin resistance precedes the progressive 
loss of insulin secretion capacity.3 Thus, the complex-
ity of the pharmacological treatment of this disease is 
closely related with disease progression, as observed in 
the United Kingdom Prospective Diabetes Study (UK-
PDS), in which 50% of the patients originally treated 
with only one drug required a second drug after three 
years, and after nine years, 75% were using multiple 
drugs, including insulin, to achieve the therapeutic 
goal (HbAC1 < 7.5).5
Diabetics, especially those treated with insulin, show 
more extensive atherosclerosis and compromised compen-
satory vascular remodelling. Nicholls et al.6 conducted a 
systematic review of five studies that used intravascular 
ultrasound, and demonstrated that, in diabetics, the ath-
eroma volume was larger and the lumen volume was 
smaller for the same volume of external elastic lamina 
when compared to non-diabetics. Moreover, insulin-treated 
patients showed lower amounts of external elastic lamina 
and lumen for the same volume of atheroma.
Due to the characteristics of higher complexity of 
coronary damage in diabetic patients, especially those 
treated with insulin, and the lack of studies in Brazil 
evaluating this population, this study analyzed, in a 
large multicenter registry, the in-hospital outcomes of 
percutaneous coronary intervention (PCI) in diabetic 
patients treated (ITD) or not (NITD) with insulin.
Methods
Population
From August 2006 to October 2012, 6,288 consecu-
tive patients underwent PCI at the centers that constitute 
the Angiocardio Registry (Hospital Bandeirantes – São 
Paulo, SP, Brazil; Rede D’Or Hospital São Luiz Analia 
Franco – São Paulo, SP, Brazil; Hospital Vera Cruz – 
Campinas, SP, Brazil; Hospital Regional do Vale do 
Paraíba – Taubaté, SP, Brazil; and Hospital Leforte 
– São Paulo, SP, Brazil), of whom 1,896 (30.2%) had 
diabetes mellitus. Data were collected prospectively and 
stored in a computer database available via internet at 
all centers participating in the registry.
The primary objective was to compare rates of major 
adverse cardiac and cerebrovascular events (MACCE), 
including death, stroke, periprocedural infarction, and 
emergency coronary artery bypass graft (CABG) surgery 
between the ITD and NITD groups. These outcomes 
were recorded at the time of hospital discharge.
Percutaneous coronary intervention
PCIs were almost entirely performed by femoral 
access; the radial approach was used as an option 
in a few cases. The choice of technique and material 
used during the procedure was at the discretion of the 
surgeons, as well as the need for glycoprotein IIb/IIIa 
inhibitors. Unfractionated heparin was used in the 
beginning of the procedure at a dose of 70 to 100 
U/kg, except in patients who were already using low 
molecular-weight heparin.
All patients received antiplatelet therapy in com-
bination with acetylsalicylic acid at loading dose of 
300 mg and maintenance dose of 100 mg/day to 200 
mg/day, and clopidogrel at loading dose of 300 mg or 
600 mg and maintenance dose of 75 mg/day. Femo-
ral sheaths were removed four hours after the start of 
heparin. Radial sheaths were removed immediately 
after the procedure.
Angiographic analysis
Analyses were performed in at least two orthogo-
nal views by experienced professionals using digital 
quantitative angiography. This study used the same 
angiographic criteria contained in the database of 
the National Centre for Cardiovascular Interventions 
(Central Nacional de Intervenções Cardiovasculares 
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– CENIC) of the Brazilian Society of Hemodynamics 
and Interventional Cardiology.7 The type of lesion was 
classified according to the American College of Cardi-
ology/American Heart Association (ACC/AHA) criteria.8 
The Thrombolysis in Myocardial Infarction (TIMI) clas-
sification was used for the determination of pre- and 
post-procedure coronary flow.9
definitions
Procedural success was defined as achievement of 
angiographic success (residual stenosis < 30% with TIMI 
3 flow), without the occurrence of death, periprocedural 
infarction, oremergency CABG. 
Deaths from any cause were recorded. Myocardial 
infarction was defined by the reappearance of angina 
symptoms with electrocardiographic alterations (new 
ST-segment elevation or new Q waves) and/or angiogra- 
phic evidence of target-vessel occlusion. Emergency 
CABG was considered when indicated by procedural 
failure or complication of the index procedure.
statistical analysis
The data stored in the Coreangio Oracle-based 
database were plotted in Excel spreadsheets and ana-
lysed using SPSS version 15.0. Continuous variables 
were expressed as means and standard deviations, 
and categorical variables were expressed as absolute 
numbers and percentages. Associations between con-
tinuous variables were assessed using the analysis 
of variance (ANOVA) model. Associations between 
categorical variables were evaluated by chi-squared 
or Fisher’s exact test or likelihood ratio, when appro-
priate. The significance level was set at P  <  0.05. 
Multivariate analysis was used to identify independent 
predictors of MACCE.
Results
Of 1,896 consecutive diabetic patients undergoing 
PCI, 397 (20.9%) were using insulin (ITD group) and 
1,499 (79.1%) were not (NITD). The mean age of both 
groups was similar (63.4 ± 10.6 years vs. 64.2 ± 10.8 
years; P = 0.22), but the ITD group had a higher propor-
tion of female patients (45.3% vs. 34.8; P < 0.01). The 
prevalence of comorbidities was not different between 
the groups, except for chronic renal failure, which 
was more frequent in the ITD group (10.1% vs. 2.6%; 
P < 0.01). The ITD group was submitted to fewer pri-
mary PCIs (4.3% vs. 8.4%; P < 0.01), performed under 
more adverse clinical conditions (Killip IV) (Table 1).
Approximately two-thirds of patients in both 
groups had single-vessel involvement; the left anterior 
descending artery was the most frequently treated 
vessel and left ventricular function was preserved in 
most patients (Table 2). Patients in the ITD group had 
some characteristics of less complex treated lesions, 
with fewer lesions of type B2/C (51.9% vs. 57.2%; P = 
0.03), thrombus (4.8% vs. 7.5%; P = 0.03), occlusions 
(6.8% vs. 11.6%; P < 0.01), and TIMI flow grade 0/1 
pre-PCI (9 % vs. 13%; P < 0.01).
Data on the procedures are shown in Table 3. A 
total of 1.4 ± 0.7 vessels/patient were treated, with 1.3 
± 0.7 stents/patient in both groups. Less than a third 
of the population received drug-eluting stents (28.3% 
vs. 31.2%; P = 0.23). The diameter (3.09 ± 0.38 mm 
vs. 3.14 ± 0.38  mm; P = 0.76) and length (18.4 ± 
7.1 mm vs. 18.7 ± 7 mm; P = 0.45) of stents did not 
differ between groups. Procedural success was high 
and similar between ITD and NITD groups (94.7% vs. 









Age, years 63.4 ± 10.6 64.2 ± 10.8 0.22
Female gender, n (%) 180 (45.3) 522(34.8) < 0.01
Smoking, n (%) 57 (14.4) 260 (17.3) 0.16
Arterial hypertension, n (%) 341 (85.9) 1,296 (86.5) 0.77
Dyslipidaemia, n (%) 203 (51.1) 704 (47) 0.14
Previous myocardial 
infarction, n (%)
82 (20.7) 279 (18.6) 0.36
Previous CABG, n (%) 52 (13.1) 241 (16.1) 0.14
Chronic renal failure, n (%) 40 (10.1) 39 (2.6) < 0.01
Previous stroke, n (%) 14 (3.5) 63 (4.2) 0.54
Previous PCI, n (%) 87 (21.9) 370 (24.7) 0.25
Clinical picture, n (%) 0.33
Asymptomatic 123 (31) 426 (28.4)
Stable angina 73 (18.4) 279 (18.7)
Acute coronary syndrome 101 (25.5) 349 (23.3)
Myocardial infarction 66 (16.6) 318 (21.2)
Ischaemic equivalent 34 (8.6) 127 (8.4)
Primary PCI, n (%) 17 (4.3) 126 (8.4) < 0.01
Rescue PCI, n (%) 7 (1.8) 37 (2.5) 0.41
Killip, n (%) 0.03
I 11 (47.8) 125 (71.4)
II 5 (21,7) 28 (16)
III 1 (4.3) 8 (4.6)
IV 6 (26.1) 14 (8)
ITD, insulin-treated diabetics; NITD, non-insulin treated diabetics; 
CABG, coronary artery bypass graft; PCI, percutaneous coronary 
intervention.
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(n = 397 patients/  
548 vessels/ 619 lesions)
NITD
(n = 1,499 patients/  
2,076 vessels/ 2,318 lesions) P-value
Affected vessels, n (%) 0.71
One 259 (65.2) 1,004 (67)
Two 112 (28.2) 385 (25.7)
Three 26 (6.5) 110 (7.3)
Treated vessels, n (%) 0.44
RCA 163 (29.7) 604 (29.1)
LCx 159 (29) 562 (27.1)
LAD 203 (37) 780 (37.6)
Grafts 20 (3.6) 113 (5.4)
LMCA 3 (0.5) 17 (0.8)
Type B2/C lesions, n (%) 282 (51.9) 1,156 (57.2) 0.03
Calcified lesions, n (%) 78 (12.6) 368 (15.9) 0.05
Lesions with thrombi, n (%) 30 (4.8) 173 (7.5) 0.03
Long lesions, n (%) 89 (14.4) 295 (12.8) 0.32
Bifurcations, n (%) 38 (6.1) 179 (7.7) 0.20
Occlusions, n (%) 42 (6.8) 268 (11.6) < 0.01
Left ventricular dysfunction, n (%) 11 (2.7) 71 (4.7) 0.12
Pre-procedural TIMI, n (%) < 0.01
0/1 56 (9) 300 (13)
2/3 563 (91) 2,010 (87)
Collateral circulation, n (%) 76 (12.3) 295 (12.7) 0.82
ITD, insulin-treated diabetics; NITD, non-insulin treated diabetics; RCA, right coronary artery; LCx, left circumflex artery; LAD, left 




n = 397 patients/  
548 vessels/ 619 lesions
NITD
n = 1,499 patients/  
2,076 vessels/ 2,318 lesions P-value
Treated vessels/patient 1.4 ± 0.7 1.4 ± 0.7 0.94
Implanted stents, n (%) 378 (95.2) 1,412 (94.2) 0.51
Stent/patient ratio 1.3 ± 0.7 1.3 ± 0.7 0.50
Stent use, n (%) 499 (91.1) 1,869 (90) 0.52
BMS 357 (71.1) 1,283 (68.8) 0.23
DES 141 (28.3) 583 (31.2)
Stent diameter, mm 3.09 ± 0.38 3.14 ± 0.38 0.76
Stent length, mm 18.4 ± 7.1 18.7 ± 7 0.45
Glycoprotein IIb/IIIa inhibitors 24 (6) 93 (6.2) > 0.99
Thrombus aspiration, n (%) 4 (1.1) 36 (2.5) 0.12
TIMI flow, post-PCI, n (%) 0.57
0/1 10 (1.7) 48 (2.2)
2/3 572 (98.3) 2,122 (97.8)
Degree of stenosis, %
Pre 80.8 ± 12.2 82.3 ± 12.7 < 0.01
Post 4.1 ± 17 4.1 ± 7.3 0.96
Procedure success, n (%) 376 (94.7) 1,434 (95.7) 0.50
ITD, insulin-treated diabetics; NITD, non-insulin-treated diabetics; BMS, bare metal stents; DES, drug-eluting stents; TIMI, Thrombolysis 
in Myocardial Infarction.
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The in-hospital clinical outcomes (Table 4) showed 
no difference in the occurrence of MACCE (3.8% vs. 
2.8%; P = 0.40), stroke (0% vs. 0.1%; P > 0.99), myo-
cardial infarction (2.5% vs. 2.1%; P = 0.72), emergency 
coronary artery bypass grafting (0% vs. 0.1%; P > 0.99) 
or death (1.5% vs. 0.8%; P = 0.24).
In the univariate analysis, the variables female 
gender, multivessel disease, lesions with thrombus, 
TIMI flow 0/1 pre-PCI, presence of collateral circula-
tion, primary PCI, rescue PCI, and adjunctive use of 
glycoprotein IIb/IIIa inhibitors showed a significant 
association with MACCE occurrence. In the multivari-
ate analysis, female gender (odds ratio [OR], 1.0203; 
95% confidence interval [95% CI] = 1.0043-1.00365; 
P = 0.01), multivessel disease (OR, 1.0296; 95% CI, 
1.0127-1.0467; P < 0.01), and TIMI flow 0/1 pre-PCI 
(OR, 1.0655; 95% CI, 1.0409 to 1.0906; P < 0.01) 
were the variables that best explained the presence of 
in-hospital MACCE (Table 5).
discussion
Diabetics treated with PCI included in the present 
study are representative of the national clinical practice, 
with a predominance of patients with stable single ves-
sel coronary artery disease and preserved ventricular 
function, mostly treated with bare-metal stents.10 Insulin-
treated diabetics, who comprised approximately one-fifth 
of the population, had greater clinical complexity than 
other patients, but lower angiographic complexity. This 
discrepancy is possibly explained by selection bias, in 
which patients with more complex anatomy are more 
likely to be referred for CABG.11
The number of treated vessels and the number of 
stents per patient corroborate the finding that angi- 
ographically less complex patients are referred for PCI. 
The limited availability of drug-eluting stents in this 
population reinforces these findings, which logically 
causes interventionists to treat patients with a lower 
number of involved vessels and less complex lesions. 
Although slightly over 50% of the lesions were type 
B2/C, the prevalence of more challenging angiographic 
characteristics, such as bifurcations and occlusions was 
low, resulting in high procedural success, which was 
similar between groups.
The use of glycoprotein IIb/IIIa inhibitors during 
PCI in diabetic patients has been recommended in 
the past decade by studies that demonstrated reduced 
major adverse cardiac events rates.12 However, due 
to the effectiveness and safety of pre-treatment with 
clopidogrel, and to the availability of new antiplatelet 
treatment associated with acetylsalicylic acid in the dual 
antiplatelet regimen, the current use of glycoprotein IIb/
IIIa has been restricted to patients with acute coronary 
syndrome with large thrombotic burden, or as rescue 
therapy in vessel occlusion during the procedure.13 
This evidence justifies the low use of this drug in the 
present registry.
The in-hospital clinical outcomes were similar 
between groups, and were consistent with a study that 
also evaluated acute events in diabetic patients treated 
or not treated with insulin.14 In fact, in a recently 
developed model with 588,398 procedures from the 
National Cardiovascular Data Registry15 to predict in-
hospital mortality, cardiogenic shock was the strongest 
predictor, followed by renal failure and age. Diabetes 
was not included in this eight-variable model.
Diabetes mellitus is a marker of poor prognosis 
in the medium- and long-term of post-PCI with higher 
incidence of angiographic and clinical events, especially 
coronary restenosis; the use of drug-eluting stents is 
recommended (class 1 indication, level of evidence 
A) to obtain best results.13 The subgroup analysis of 
the Drug-Eluting Stent in the Real World (DESIRE) 
registry, which assessed the late outcome after PCI 
with drug-eluting stents in diabetic and non-diabetic 
patients, confirmed these findings in Brazil.16 In the 





(n = 1,499) P-value
MACCE, n (%) 15 (3.8) 42 (2.8) 0.40
Stroke, n (%) 0 (0) 1 (0.1) > 0.99
Myocardial 
infarction, n (%)
10 (2.5) 31 (2.1) 0.72
Emergency CABG, 
n (%)
0 (0) 1 (0.1) > 0.99
In-hospital death, 
n (%)
6 (1.5) 12 (0.8) 0.24
ITD, insulin-treated diabetics; NITD, non-insulin treated 
diabetics; MACCE, major adverse cardiac and cerebrovascular 
events; CABG, coronary artery bypass graft surgery.
Table 5  
Independent predictors of in-hospital major cardiac 
and cerebrovascular events in diabetic patients
Factors Or 95% CI p-value
Female 
gender
1.0203 [1.0043; 1.0365] 0.01
Multivessel 
disease
1.0296 [1.0127; 1.0467] < 0.01
TIMI flow  
0/1 pre-PCI
1.0655 [1.0409; 1.0906] < 0.01
95% CI, 95% confidence interval; OR, odds ratio; TIMI, 
Thrombolysis in Myocardial Infarction.
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present registry, drug-eluting stents were used in ap-
proximately one-third of the patients; this rate was not 
higher because the Brazilian Unified Health System 
does not yet provide these devices.
study limitation
The limitations of this study were the retrospective 
analysis of data and the absence of late follow-up.
conclusion
In the present study, ITD was not an independent 
predictor of hospital MACCE.
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